Term ends Mar 25, 2033 · High confidence
20-year base term ends Mar 19, 2028
Filed Sep 17, 2009 as application 12/531,839 · Granted Dec 6, 2011
Base term plus 303 days of patent term adjustment (USPTO delay)
Today
2008
2033
Clock starts
Mar 19, 2008
Mar 19, 2008
Term ends
Mar 25, 2033
Mar 25, 2033
Granted
Dec 6, 2011
Dec 6, 2011
base term
patent term adjustment
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
303
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 303 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 19, 2008, when application PCT/AT2008/000097, the earliest non-provisional in its chain, was filed (this one was filed Sep 17, 2009) | Mar 19, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +303 days, USPTO patent term adjustment record | Jan 16, 2029 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | +1529 days, USPTO 35 U.S.C. 156 certificate | added to Jan 16, 2029: Mar 25, 2033 | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 25, 2033 | High confidence |
Partial family
| Application PCT/AT2008/000097 | PCT application no patent term | no patent term |
| US 8,071,643 | this patent Mar 2033 | Mar 2033 |
| US 8,153,689 | In force Mar 2028 | Mar 2028 |
| Application 13/438,160 | Abandoned not computed | not computed |
| Application 14/283,734 | Abandoned not computed | not computed |
| Application 15/480,756 | Abandoned not computed | not computed |
| Application 16/023,880 | Abandoned not computed | not computed |
| Application 16/277,143 | Abandoned not computed | not computed |
8 of 13 applications in this family shown, earliest filings first. Partial: 1 of the 13 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 17, 2009 Reel 23249, frame 229 | Mang, Rosemarie; Heilmayer, Werner; Badegruber, Rudolf; Strickmann, Dirk B.; Novak, Rodger; Ferencic, Mathias; Bulusu, Atchyuta Rama Chandra Murty | Nabriva Therapeutics AG | Assignment of Assignor's Interest |
| Oct 13, 2014 Reel 33935, frame 48 | Nabriva Therapeutics AG | Kreos Capital IV (UK) Limited | Assignment of Assignor's Interest |
| Sep 29, 2016 Reel 39894, frame 473 | Kreos Capital IV (UK) Limited | Nabriva Therapeutics AG | Release of Security Interest |
| Jul 18, 2018 Reel 47958, frame 106 | Nabriva Therapeutics AG | Nabriva Therapeutics GmbH | Change of Name |
| Dec 20, 2018 Reel 47973, frame 110 | Nabriva Therapeutics GmbH | Hercules Capital, Inc. | Intellectual Property Security Agreement |
| Jan 18, 2019 Reel 48062, frame 807 | Nabriva Therapeutics GmbH | Hercules Capital, Inc. | Security Interest |
| Mar 3, 2023 Reel 62881, frame 90 | Hercules Capital, Inc. | Nabriva Therapeutics GmbH; Zavante Therapeutics, Inc. | Release of Security Interest |
| Mar 3, 2023 reel/frame not recorded | Hercules Capital, Inc. | Nabriva Therapeutics GmbH | Release of Security Interest |
| Mar 3, 2023 reel/frame not recorded | Hercules Capital, Inc. | Zavante Therapeutics, Inc. | Release of Security Interest |
| Jun 20, 2023 Reel 64312, frame 350 | Hercules Capital, Inc. | Nabriva Therapeutics GmbH | Corrective Assignment to Correct the Receiving Party Data and the Assignment Document Previously Recorded at Reel: 062881 Frame: 0090. Assignor(S) Hereby Confirms the Release of Security Interest. |
| Jan 9, 2025 Reel 69806, frame 458 | Nabriva Therapeutics GmbH | Hong Kong King-Friend Industrial Company Ltd. | Assignment of Assignor's Interest |
| Apr 3, 2025 Reel 70725, frame 291 | Nabriva Therapeutics GmbH | Hong Kong King-Friend Industrial Company Ltd. | Nunc Pro Tunc Assignment |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2033
Term ends Mar 25, 2033. No further fees fall due before then
Note
The 303 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
15
later US patents cite this one
That is above the median of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.